HER2-Targeted Dendritic Cell Vaccine Shows Promise for Treating Patients with Early-Stage Breast Cancer

Researchers from the Moffitt Cancer Center in Tampa, Florida report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.

 News Medical Net